- Home
- MTN vs NUVL Comparison
MTN vs NUVL Comparison
Compare MTN & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTN
- NUVL
- Stock Information
- Founded
- MTN 1997
- NUVL 2017
- Country
- MTN United States
- NUVL United States
- Employees
- MTN 52500
- NUVL N/A
- Industry
- MTN Services-Misc. Amusement & Recreation
- NUVL Biotechnology: Pharmaceutical Preparations
- Sector
- MTN Consumer Discretionary
- NUVL Health Care
- Exchange
- MTN Nasdaq
- NUVL Nasdaq
- Market Cap
- MTN 5.2B
- NUVL 5.6B
- IPO Year
- MTN 1997
- NUVL 2021
- Fundamental
- Price
- MTN $144.39
- NUVL $69.85
- Analyst Decision
- MTN Hold
- NUVL Strong Buy
- Analyst Count
- MTN 10
- NUVL 8
- Target Price
- MTN $190.00
- NUVL $115.50
- AVG Volume (30 Days)
- MTN 574.2K
- NUVL 625.4K
- Earning Date
- MTN 06-05-2025
- NUVL 05-08-2025
- Dividend Yield
- MTN 6.14%
- NUVL N/A
- EPS Growth
- MTN 10.73
- NUVL N/A
- EPS
- MTN 6.89
- NUVL N/A
- Revenue
- MTN $2,946,168,000.00
- NUVL N/A
- Revenue This Year
- MTN $4.64
- NUVL N/A
- Revenue Next Year
- MTN $4.21
- NUVL N/A
- P/E Ratio
- MTN $20.99
- NUVL N/A
- Revenue Growth
- MTN 3.57
- NUVL N/A
- 52 Week Low
- MTN $129.85
- NUVL $55.54
- 52 Week High
- MTN $206.38
- NUVL $113.51
- Technical
- Relative Strength Index (RSI)
- MTN 51.57
- NUVL 46.22
- Support Level
- MTN $136.91
- NUVL $63.56
- Resistance Level
- MTN $143.01
- NUVL $78.97
- Average True Range (ATR)
- MTN 3.79
- NUVL 3.46
- MACD
- MTN 1.25
- NUVL -0.38
- Stochastic Oscillator
- MTN 91.60
- NUVL 40.84
About MTN Vail Resorts Inc.
Vail Resorts Inc Bhd is a resorts and casinos company that operates mountain resorts and ski areas. The company has three business segments that include Mountain, Lodging, and Real Estate. The Mountain segment operates numerous ski resort properties that offer a variety of winter and summer activities, such as skiing, snowboarding, snowshoeing, hiking, and mountain biking. The Lodging segment owns and operates hotels and condominiums. The Real Estate segment owns, develops, and leases real estate, typically near its other properties. The company generates the vast majority of its revenue within the United States.
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.